Washington State University, Program of Excellence in the Addictions, USA.
J Exp Anal Behav. 2012 May;97(3):323-31. doi: 10.1901/jeab.2012.97-323.
Gamma-hydroxybutyrate (GHB) is a drug with significant abuse potential. The present study aimed to assess the relative value of escalating doses of GHB to current GHB users via the Multiple Choice Procedure (MCP), and to validate that the dose rated highest with the MCP would be self-administered at a greater rate than placebo. Participants were 5 current GHB users who were not currently trying to stop using GHB. To examine the value of escalating doses of GHB, the following doses of GHB were used: 0 (placebo), 12.5, 25, 37.5, and 50 mg/kg. Participants typically assigned higher doses of GHB had higher crossover points on the MCP. During choice sessions, participants made repeated choices between administering GHB, placebo or nothing. All participants selected GHB exclusively (5 out of 5 instances) except for one participant who selected GHB on 4 out of 5 instances, thus 96% (i.e., 24/25) of choices were for active GHB. Based on these data, GHB appears likely to function as a dose-dependent reinforcer for humans based on our sample.
γ-羟基丁酸（GHB）是一种具有显著滥用潜力的药物。本研究旨在通过多项选择程序（MCP）评估递增剂量的 GHB 对当前 GHB 用户的相对价值，并验证 MCP 评定的最高剂量会比安慰剂更被自我给药。参与者为 5 名当前正在使用 GHB 的 GHB 用户，但他们目前并不试图停止使用 GHB。为了研究递增剂量的 GHB 的价值，使用了以下剂量的 GHB：0（安慰剂）、12.5、25、37.5 和 50mg/kg。在 MCP 上，通常分配更高剂量 GHB 的参与者具有更高的交叉点。在选择过程中，参与者在给予 GHB、安慰剂或什么都不给之间反复做出选择。所有参与者都选择了 GHB（5 次中有 5 次），除了一名参与者有 4 次选择了 GHB，因此 96%（即 24/25）的选择是为了活性 GHB。根据这些数据，基于我们的样本，GHB 似乎很可能是一种剂量依赖性的人类强化物。
